Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP5 | Q13451 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.33 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1688444 | 0.98 | FKBP5 (0.36) | FKBP5CRBNGRIN1GRIN2AOR51E2 | |
| SCHEMBL1997375 | 0.93 | — | — | |
| SCHEMBL9320311 | 0.76 | FKBP5 (0.37) | FKBP5CRBNGRIN1GRIN2AOR51E2 | |
| SCHEMBL9129408 | 0.75 | CRBN (0.40) | FKBP5CRBNGRIN1GRIN2AOR51E2 | |
| SCHEMBL6673999 | 0.73 | FKBP5 (0.39) | FKBP5CRBNGRIN1GRIN2AOR51E2 | |
| SCHEMBL11316947 | 0.73 | FKBP5 (0.39) | FKBP5CRBNGRIN1GRIN2AOR51E2 | |
| SCHEMBL23009712 | 0.71 | FKBP5 (0.37) | FKBP5CRBNGRIN1GRIN2AOR51E2 | |
| SCHEMBL11723152 | 0.71 | FKBP5 (0.37) | FKBP5CRBNGRIN1GRIN2AOR51E2 | |
| SCHEMBL466252 | 0.71 | FKBP5 (0.37) | FKBP5CRBNGRIN1GRIN2AOR51E2 | |
| SCHEMBL6118648 | 0.71 | FKBP5 (0.37) | FKBP5CRBNGRIN1GRIN2AOR51E2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0804530-A1 | BLEACHING COMPOSITIONS AND ADDITIVES COMPRISING BLEACH ACTIVATORS HAVING ALPHA-MODIFIED LACTAM LEAVING-GROUPS | THE PROCTER & GAMBLE COMPANY (US) | 1997-11-05 | — | — | EP | claimed |
| WO-1996022350-A1 | BLEACHING COMPOSITIONS AND ADDITIVES COMPRISING BLEACH ACTIVATORS HAVING ALPHA-MODIFIED LACTAM LEAVING-GROUPS | THE PROCTER & GAMBLE COMPANY (US) | 1996-07-25 | — | — | WO | claimed |
| US-4003907-A | Δ1 -1-Azacycloalkene-2-carboxylic acids and their production | BAYER AKTIENGESELLSCHAFT (DT) | 1977-01-18 | — | — | US | claimed |
| US-20210206725-A1 | PIPERLONGUMINE ANALOGUES AND USES THEREOF | BIOVENTURES, LLC | 2021-07-08 | — | — | US | disclosed |
| EP-0804530-A1 | BLEACHING COMPOSITIONS AND ADDITIVES COMPRISING BLEACH ACTIVATORS HAVING ALPHA-MODIFIED LACTAM LEAVING-GROUPS | THE PROCTER & GAMBLE COMPANY (US) | 1997-11-05 | — | — | EP | disclosed |
| US-5635103-A | Bleaching compositions and additives comprising bleach activators having alpha-modified lactam leaving-groups | THE PROCTER & GAMBLE COMPANY (US) | 1997-06-03 | — | — | US | disclosed |
| WO-1996022350-A1 | BLEACHING COMPOSITIONS AND ADDITIVES COMPRISING BLEACH ACTIVATORS HAVING ALPHA-MODIFIED LACTAM LEAVING-GROUPS | THE PROCTER & GAMBLE COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| EP-0381622-B1 | Method for the production of dihalogenobutyraldehydes | CIBA GEIGY AG (CH) | 1994-03-16 | — | — | EP | disclosed |
| US-5015780-A | Process for the preparation of dihalobutyraldehydes | CIBA-GEIGY CORPORATION (US) | 1991-05-14 | — | — | US | disclosed |
| US-4680392-A | Substituted caprolactam derivatives as antihypertensives | MERCK & CO., INC. (US) | 1987-07-14 | — | — | US | disclosed |
| US-4629787-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | MERCK & CO., INC. (US) | 1986-12-16 | — | — | US | disclosed |
| EP-0046291-B1 | SUBSTITUTED CAPROLACTAM DERIVATIVES AS ANTIHYPERTENSIVES, PROCESS FOR PREPARING THEM, PHARMACEUTICAL COMPOSITION CONTAINING THEM, AND INTERMEDIATES | MERCK & CO. INC. (US) | 1985-12-27 | — | — | EP | disclosed |
| EP-0046291-A2 | Substituted caprolactam derivatives as antihypertensives, process for preparing them, pharmaceutical composition containing them, and intermediates | MERCK & CO. INC. (US) | 1982-02-24 | — | — | EP | disclosed |
| US-4044001-A | Process for preparing α-chloro-ε-caprolactam | ALLIED CHEMICAL CORPORATION (US) | 1977-08-23 | — | — | US | disclosed |
| US-4003907-A | Δ1 -1-Azacycloalkene-2-carboxylic acids and their production | BAYER AKTIENGESELLSCHAFT (DT) | 1977-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206725-A1 | PIPERLONGUMINE ANALOGUES AND USES THEREOF | AGER, MCL1, TP53 | FKBP5 3236/4885CRBN 1364/4885GRIN1 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.